Meet the Founder


        Founded in November 2019, Innorna is committed to delivering innovative and advanced mRNA medicines to everyone in need. We are pioneers in the research and development of mRNA-based vaccines and therapeutics for infectious diseases, cancers and rare diseases. Innorna is one of the few companies in the world that has the proprietary mRNA delivery platform.
       Up to 2021, Innorna has raised over 1 billion RMB from reputable venture capital firms. Our headquarter is located in Hong Kong Science Park.


Dr. Li Linxian

Meet the Founder

-Assistant professor at Karolinska Institute
-“35 Innovators Under 35 in China” by MIT Technology Review
-Developed the next-generation LNP platform for mRNA delivery
      Using his 10 years of biotech experience, along with his passion to use technology to ease patients’ pain, Dr. Li and his team were able to develop the LNP platform for safely and effectively delivering the mRNA into the right cells and commercialize this innovation to serve the wider society, presenting a revolutionary step toward expanding the clinical application of mRNA.

Our Big Moments

2021 3

Completed Series A financing

2021 4

Started the setup of the 3000㎡ Phase I laboratory and the 2500㎡ CMC Center in Shenzhen

2021 7

Completed the mRNA bio-engineering production workflow

2021 9

Launched Phase I laboratory in Shenzhen R&D Center
Launched Hong Kong R&D center

2021 11

Completed ~$800 million RMB (120 million USD) Series B financing

2020 2

Submitted the 1st China patent

2020 4

Signed the strategic partnership agreement with Chongqing Zhifei Biological Product Co., Ltd (the top vaccine enterprise in China)

2020 8

Completed Angel financing
Submitted the 2nd China patent application

2020 9

Signed the strategic partnership agreements with Chongqing Zhifei Biological Products Co., Ltd (the top vaccine enterprise in China) on mRNA vaccine
Submitted the 3rd China patent application

2020 11

Completed the strategic investor financing

2019 11

Company established